# Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

> **NCT00602511** · PHASE3 · COMPLETED · sponsor: **Nordic Myeloma Study Group** · enrollment: 300 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00602511
- **Lead sponsor:** Nordic Myeloma Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-09
- **Final completion:** 2010-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2011-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602511, "Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00602511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*